EP Patent

EP3351248B1 — Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders

Assigned to Ardelyx Inc · Expires 2021-06-09 · 5y expired

What this patent protects

Patent listed against tenapanor-hydrochloride.

Drugs covered by this patent

tenapanor-hydrochloride (TENAPANOR HYDROCHLORIDE)

Patent Metadata

Patent number: EP3351248B1
Jurisdiction: EP
Classification: —
Expires: 2021-06-09
Drug substance claim: No
Drug product claim: No
Assignee: Ardelyx Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.